Stock ENLV ENLIVEX THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Enlivex Therapeutics Ltd. Stock

Equities

ENLV

IL0011319527

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-06-25 EDT 		5-day change 1st Jan Change
1.36 USD -3.55% Intraday chart for Enlivex Therapeutics Ltd. -2.16% -49.63%
06-24 Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial MT
06-24 Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis CI

Financials

Sales 2024 * - Sales 2025 * - Capitalization 28.39M 38.77M
Net income 2024 * -17M -23.22M Net income 2025 * -14M -19.12M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.68 x
P/E ratio 2025 *
-2.31 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.17%
More Fundamentals * Assessed data

Chart Enlivex Therapeutics Ltd.

Dynamic Chart

Latest news about Enlivex Therapeutics Ltd.

Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial MT
Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis CI
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
HC Wainwright Adjusts Price Target on Enlivex Therapeutics to $6 From $7, Maintains Buy Rating MT
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis CI
Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall MT
Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial MT
Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis CI
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark MT
Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis CI
HC Wainwright Adjusts Enlivex Therapeutics Price Target to $7 From $12, Maintains Buy Rating MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care MT
Enlivex Therapeutics Shares Fall After Topline Data from Sepsis Treatment Study MT
More news

Analyst Recommendations on Enlivex Therapeutics Ltd.

HC Wainwright Adjusts Price Target on Enlivex Therapeutics to $6 From $7, Maintains Buy Rating MT
HC Wainwright Adjusts Enlivex Therapeutics Price Target to $7 From $12, Maintains Buy Rating MT
HC Wainwright Cuts Enlivex Therapeutics Price Target to $12 From $15, Maintains Buy Rating MT
HC Wainwright Adjusts Enlivex Therapeutics' Price Target to $15 from $33, Keeps Buy Rating MT
More recommendations

Press releases Enlivex Therapeutics Ltd.

Enlivex Therapeutics : Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating Allocetra in up to 46 Patients with Thumb Osteoarthritis PU
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis GL
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis AQ
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 GL
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 AQ
More press releases

Quotes and Performance

1 day-3.55%
1 week-2.16%
1 month-2.86%
3 months-63.04%
6 months-53.42%
Current year-49.63%
More quotes

Highs and lows

1 week
1.26
Extreme 1.2602
1.48
1 month
1.18
Extreme 1.18
1.66
Current year
1.15
Extreme 1.15
4.59
1 year
1.15
Extreme 1.15
4.59
3 years
1.15
Extreme 1.15
13.95
5 years
1.15
Extreme 1.15
44.90
10 years
1.15
Extreme 1.15
44.90
More quotes

Managers and Directors - Enlivex Therapeutics Ltd.

Managers TitleAgeSince
Oren Hershkovitz CEO
 Chief Executive Officer 47 19-11-15
Dror Mevorach FOU
 Founder 68 08-12-31
Shachar Shlosberger DFI
 Director of Finance/CFO 47 15-12-31
Members of the board TitleAgeSince
Shai Novik CHM
 Chairman 58 13-12-31
Avri Havron BRD
 Director/Board Member 76 13-12-31
Brian Schwartz BRD
 Director/Board Member 52 20-11-30
More insiders

Quotes

Date Price Change Volume
24-06-25 1.36 -3.55% 129,037
24-06-24 1.41 +3.68% 102,487
24-06-21 1.36 +2.79% 32,687
24-06-20 1.323 +2.57% 75,972
24-06-18 1.29 -7.19% 117,127

Delayed Quote Nasdaq, June 25, 2024 at 04:30 pm

More quotes

Company Profile

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Sector
Biotechnology & Medical Research
Calendar
2025-05-22 - Q1 2025 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.36 USD
Average target price
6 USD
Spread / Average Target
+341.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ENLIVEX THERAPEUTICS LTD. Stock Enlivex Therapeutics Ltd.
-49.63% 29.43M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.45% 123B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.96% 115B
ARGENX SE Stock argenx SE
+23.73% 25.85B
BIONTECH SE Stock BioNTech SE
-20.05% 20.9B
BEIGENE, LTD. Stock BeiGene, Ltd.
-16.28% 16.77B
GENMAB A/S Stock Genmab A/S
-16.52% 16.52B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.35% 15.56B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.91% 15.49B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.52% 13.45B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ENLV Stock